Skip to content

MyGeneRank: A Digital Platform for Next-Generation Genetic Studies

MyGeneRank: A Digital Platform for Next-Generation Genetic Studies

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03277365
Enrollment
100000
Registered
2017-09-11
Start date
2017-09-26
Completion date
2030-09-30
Last updated
2024-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Diseases

Brief summary

Many conditions affecting health are caused by a combination of environment, behaviors, and genes. While individuals can alter some factors in their lives to reduce the chances of developing different diseases (e.g., not smoking cigarettes), the contribution from genetic risk encoded by DNA remains with people throughout their lives. Scientists are still trying to determine the entirety of genetic factors that influence disease, but for some conditions it has been shown that the factors identified thus far can begin to identify people at high to low genetic risk. Looking across the genome, scientists can calculate a cumulative genetic risk score - which can be used to rank genetic risk compared to other worldwide populations. The goal of this study is to determine how genetic risk influences health decisions and other things that can be controlled in life. The first genetic risk score is calculated for coronary heart disease (CAD). CAD ultimately leads to heart attacks, heart failure and sometimes sudden cardiac death and is the main reason heart disease remains as the number one cause of death worldwide. Other researchers have shown that this genetic risk score can be used to identify people with low, intermediate, and high risk for coronary heart disease. It has also been shown that the use of statins (cholesterol lowering drugs) provides greater benefit and protection against heart attack for people with high genetic risk for coronary artery disease. Leveraging the Apple ResearchKit and the ResearchKit linked 23andMe API, customers of 23andMe are able to provide researchers access to their genomic data. Participants will use the ResearchKit app to provide consent, view study information, answer surveys, and contact the study team. Participants will be asked to complete 3 surveys. One before viewing genetic risk scores, one immediately after viewing scores, and one 6 months after viewing scores.

Interventions

OTHERReceive genetic risk information

Risk scores are provided by ResearchKit app.

Sponsors

Scripps Translational Science Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Customer of 23andMe willing to share their 23andMe data * User of Apple mobile device

Exclusion criteria

* Under 18 years old

Design outcomes

Primary

MeasureTime frameDescription
Initiation of Statin Therapy6 monthsParticipant begins taking Statin as indicated by survey.

Countries

United States

Contacts

Primary ContactJennifer Wagner, RN
generank@scripps.edu858-784-2028

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026